Vallon Pharmaceuticals Inc.

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Novo Nordisk Brings Embark Home After F

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Mersana Ends 2022 With Third Big Pharma

Restructuring announcements and plans to lay off significant numbers of employees unfortunately have become the norm rather than the exception in 2022 as biopharmaceutical company stock prices sink an

A panel of drug developers, investors and advisors discussed the merits of going public in the US through an initial public offering or through a merger with a special purpose acquisition corporation